Show simple item record

dc.contributor.authorLiao, Zhengfa
dc.contributor.authorXu, Xiaojia
dc.contributor.authorLiang, Yaping
dc.contributor.authorXiong, Yongzhen
dc.contributor.authorChen, Ruoling
dc.contributor.authorNi, Jindong
dc.date.accessioned2017-06-14T15:05:43Z
dc.date.available2017-06-14T15:05:43Z
dc.date.issued2016-07-26
dc.identifier.citationEffect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: A systematic literature review and meta-analysis Human Vaccines & Immunotherapeutics, 12(11), pp. 2909-2915.
dc.identifier.issn2164-5515
dc.identifier.doi10.1080/21645515.2016.1201623
dc.identifier.urihttp://hdl.handle.net/2436/620517
dc.description.abstractBooster influenza vaccination has been recommended for patients with chronic renal disease in order to enhance the immune response to the influenza vaccine; however, the efficacy of a booster influenza vaccination is a matter of controversy. Therefore, we made a meta-analysis to determine the efficacy in patients with hemodialysis (HD), peritoneal dialysis (PD) and renal transplant recipient (RT). The sero-protection rate was used as a serologic parameter to describe the immune response to the vaccine. Statistical analysis was performed to calculate the pooled rate difference (RD) and 95% confidence interval (CI). The pooled RD for the H1N1, H3N2 and B influenza vaccines was 0.02 (95% CI: −0.02–0.06), 0.05 (95% CI: −0.01–0.11), 0.04 (95% CI: −0.02–0.10), respectively. We concluded that a booster dose of the influenza vaccine did not effectively enhance immunogenicity. Therefore, a booster dose of vaccine is not recommended for patients with hemodialysis, peritoneal dialysis and renal transplant recipients.
dc.description.sponsorshipNatural Science Foundation of Guangdong Province, China
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.urlhttps://www.tandfonline.com/doi/full/10.1080/21645515.2016.1201623
dc.subjectEffectiveness
dc.subjectInfluenza vaccine
dc.subjecthemodialysis
dc.subjectperitoneal dialysis
dc.subjectrenal transplant
dc.subjectrecipients
dc.subjectmeta-analysis
dc.titleEffect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: A systematic literature review and meta-analysis
dc.typeJournal article
dc.identifier.journalHuman Vaccines & Immunotherapeutics
dc.date.accepted2016-06-10
rioxxterms.funderUniversity of Wolverhampton
rioxxterms.identifier.projectUoW140617RC
rioxxterms.versionAM
rioxxterms.licenseref.urihttps://creativecommons.org/CC BY-NC-ND 4.0
rioxxterms.licenseref.startdate2017-07-01
dc.source.volume12
dc.source.issue11
dc.source.beginpage2909
dc.source.endpage2915
refterms.dateFCD2018-10-19T09:01:27Z
refterms.versionFCDAM
refterms.dateFOA2017-07-01T00:00:00Z
html.description.abstractBooster influenza vaccination has been recommended for patients with chronic renal disease in order to enhance the immune response to the influenza vaccine; however, the efficacy of a booster influenza vaccination is a matter of controversy. Therefore, we made a meta-analysis to determine the efficacy in patients with hemodialysis (HD), peritoneal dialysis (PD) and renal transplant recipient (RT). The sero-protection rate was used as a serologic parameter to describe the immune response to the vaccine. Statistical analysis was performed to calculate the pooled rate difference (RD) and 95% confidence interval (CI). The pooled RD for the H1N1, H3N2 and B influenza vaccines was 0.02 (95% CI: −0.02–0.06), 0.05 (95% CI: −0.01–0.11), 0.04 (95% CI: −0.02–0.10), respectively. We concluded that a booster dose of the influenza vaccine did not effectively enhance immunogenicity. Therefore, a booster dose of vaccine is not recommended for patients with hemodialysis, peritoneal dialysis and renal transplant recipients.


Files in this item

Thumbnail
Name:
Zhengfa Liao NI JD 2016 proof.pdf
Size:
549.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record